<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72253">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01982942</url>
  </required_header>
  <id_info>
    <org_study_id>NN102 SPRINT - MS</org_study_id>
    <secondary_id>1U01NS082329-01A1</secondary_id>
    <secondary_id>RG 4778-A-6</secondary_id>
    <nct_id>NCT01982942</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis</brief_title>
  <official_title>A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediciNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MediciNova</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study
      designed to evaluate the safety, tolerability and activity of ibudilast administered twice
      daily over a 96 week period in subjects with primary or secondary progressive multiple
      sclerosis who are currently untreated with long-term MS disease modifying therapy (DMT) or
      who are receiving either glatiramer acetate (GA) or interferon beta (IFNβ-1a [Avonex, Rebif]
      or IFNβ-1b [Betaseron Etavia]) treatment.  Study drug will be administered as an adjunct to
      glatiramer or beta interferon treatment. A total of 250 male and female subjects from 21 to
      65 years old, inclusive, are planned to be enrolled into two treatment groups.
      Randomization of subjects will be stratified by disease status (primary progressive multiple
      sclerosis or secondary progressive multiple sclerosis) and immunomodulating therapy status:
      current use of immunomodulating therapy or no current use of immunomodulating therapy.

      The study will consist of a screening phase (up to 30 days) followed by a treatment phase
      (96 weeks) and a follow-up visit (1 month post Week 96 visit).  Following the screening
      phase, subjects who continue to meet entry criteria will be randomly assigned to 1 of 2
      treatment groups:  ibudilast 100 mg/day or matching-placebo in a 1:1 ratio.  Study drug will
      be administered twice daily (BID), i.e., ibudilast 50 mg or placebo taken in the morning and
      evening).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Covariate-adjusted mean rate of change in brain atrophy over 96 weeks as measured by brain parenchymal fraction (BPF).</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the activity of ibudilast (100 mg/day) versus placebo at 96 weeks as measured by quantitative magnetic resonance imaging (MRI) analysis for whole brain atrophy using brain parenchymal fraction (BPF).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Measures: TEAEs (treatment-emergent adverse events), TESAEs (treatment-emergent serious adverse events), treatment discontinuations due to TEAEs, laboratory measures (chemistry, hematology, urinalysis), vital signs, electrocardiograms (ECGs).</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the safety and tolerability of ibudilast (100 mg/day) versus placebo  administered orally in subjects with primary progressive multiple sclerosis (PPMS) and secondary  progressive multiple sclerosis (SPMS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diffusion tensor imaging (DTI) in descending pyramidal white matter tracts</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetization transfer ratio (MTR) imaging in normal-appearing brain tissue</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal nerve fiber layer as measured by Optical coherence tomography (OCT)</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical atrophy as measured by cortical longitudinal atrophy detection algorithm [CLADA]</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory disease activity, as measured by T1 lesion volume, T2 lesion volume, and annualized relapse rate</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability, as measured by Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC)</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, as measured by Multiple Sclerosis Impact Scale (MSIS-29), EuroQol 5 Dimensions (EQ-5D), and Short Form-36 Health Survey (SF-36)</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive impairment, as measured by Symbol Digit Modalities Test (SDMT) and the Selective Reminding Test (SRT).</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic pain, as measured by Brief Pain Inventory (BPI)</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Multiple Sclerosis, Primary Progressive</condition>
  <condition>Multiple Sclerosis, Secondary Progressive</condition>
  <arm_group>
    <arm_group_label>ibudilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 100 mg/d ibudilast for 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo for 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibudilast</intervention_name>
    <arm_group_label>ibudilast</arm_group_label>
    <other_name>MN-166</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent is obtained and willing and able to comply with the protocol
             in the opinion of the Investigator.

          -  Male or female subjects ages 21 to 65, inclusive

          -  Confirmed diagnosis of SPMS or primary progressive multiple sclerosis (PPMS)
             according to 2010 International Panel Criteria

          -  Typical MS lesions on MRI according to Swanton's MRI Criteria (at least one lesion in
             two or more of the following regions: periventricular, juxtacortical, infratentorial
             [brainstem/cerebellum], spinal cord)

          -  EDSS 3.0-6.5, inclusive

          -  Clinical evidence of disability progression in the preceding two years, as measured
             by any of the following (excluding progression during clinical relapses):

               -  worsening overall EDSS of at least 0.5 points (may be assessed retrospectively
                  but cannot be during a clinical relapse) or

               -  20% worsening in 25-foot walk (25-FW) or

               -  20% worsening in 9-hole peg test (9-HPT) in either hand

          -  Existing multiple sclerosis pharmacotherapy status may include interferon-beta or
             glatiramer acetate or none (i.e. untreated).

          -  Females of child-bearing potential must have a negative serum ß-hCG at screening and
             must be willing to use appropriate contraception (as defined by the investigator) for
             the duration of study treatment and 30 days after the last dose of study treatment.

          -  Males should practice contraception as follows:  condom use and contraception by
             female partner.

          -  Subject is in good physical health on the basis of medical history, physical
             examination, and laboratory screening, as defined by the investigator.

          -  Subject is willing and able to comply with the protocol assessments and visits, in
             the opinion of the study nurse/coordinator and the Investigator.

        Exclusion Criteria:

          -  Progressive neurological disorder other than SPMS or PPMS

          -  Relapse and/or systemic corticosteroid steroid treatment for multiple sclerosis
             within 3 months of screening.  Inhaled or topical steroids are allowed.

          -  Current use of intermittent systemic corticosteroids (i.e., monthly or bimonthly
             intravenous methylprednisolone)

          -  Use of oral immunosuppressants (e.g. azathioprine, methotrexate, cyclosporine,
             teriflunomide [Aubagio®]) within 6 months of screening

          -  Use of mitoxantrone, natalizumab, or IVIg within 6 months of screening

          -  Use of fingolimod or dimethyl fumarate [Tecfidera®]  within 3 months of screening

          -  Use of rituximab or other B-cell therapy within 12 months of screening

          -  Current use of other MS disease-modifying therapies (DMTs) besides glatiramer
             acetate, IFNβ-1 (any formulation), and the above listed medications.

          -  Current use of cimetidine, cyclosporine, dronedarone, lopinavir, probenecid,
             quinidine (including Neudexta), ranolazine, rifampin, ritonavir, or tipranavir.

          -  Clinically significant cardiovascular disease, including myocardial infarct within
             last 6 months, unstable ischemic heart disease, congestive heart failure or angina

          -  Resting pulse &lt; 50 bpm, sinoatrial (SA) or atrioventricular (AV) block, uncontrolled
             hypertension, or QTcF  &gt; 450 ms

          -  Clinically significant pulmonary conditions, including severe chronic obstructive
             pulmonary disease (COPD), fibrosis, or  tuberculosis

          -  Evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of
             clinically significant impaired hepatic function through clinical and laboratory
             evaluation including ALP &gt; 1.5x ULN; ALT or AST &gt; 2x ULN; GGT &gt; 3x ULN

          -  Immune system disease (other than multiple sclerosis and autoimmune thyroid disease)

          -  History of stomach or intestinal surgery or any other condition that could interfere
             with or is judged by the Investigator to interfere with absorption, distribution,
             metabolism, or excretion of study drug.

          -  Any significant laboratory abnormality which, in the opinion of the Investigator, may
             put the subject at risk and with the following laboratory abnormalities at screening:

               -  Creatinine:  females &gt; 0.95 mg/dL; males &gt; 1.17 mg/dL

               -  WBCs  &lt; 3,000 mm3

               -  Lymphocytes &lt; 800 mm3

               -  Platelets &lt; 90,000 mm3

          -  History of malignancy &lt; 5 years prior to signing the informed consent, except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical
             cancer.

          -  History of HIV (human immunodeficiency virus), clinically significant chronic
             hepatitis, or other active infection.

          -  Subject currently has a clinically significant medical condition (other than MS)
             including the following: neurological, psychiatric, metabolic, hepatic, renal,
             hematological, pulmonary, cardiovascular (including uncontrolled hypertension),
             gastrointestinal,  urological disorder, or central nervous system (CNS) infection
             that would pose a risk to the subject if they were to participate in the study or
             that might confound the results of the study.

        Note: Active medical conditions that are minor or well-controlled are not exclusionary if,
        in the judgment of the Investigator, they do not affect risk to the subject or the study
        results. In cases in which the impact of the condition upon risk to the subject or study
        results is unclear, the Medical Safety Monitor should be consulted.

          -  Subjects with moderate to severe depression as determined by the Beck Depression
             Inventory-Fast Screen (BDI-FS).

          -  Subject has a history of alcohol or substance abuse (DSM-IV-TR criteria) within 3
             months prior to screening or alcohol or substance dependence (DSM-IV-TR criteria)
             within 12 months prior to screening. The only exceptions include caffeine or nicotine
             abuse/dependence.

          -  Subject has poor peripheral venous access that will limit the ability to draw blood
             as judged by the Investigator.

          -  Subject is currently participating, or has participated in, a study with an
             investigational or marketed compound or device within 3 months prior to signing the
             informed consent.

          -  Subject is unable to cooperate with any study procedures, unlikely to adhere to the
             study procedures and keep appointments, in the opinion of the Investigator, or was
             planning to relocate during the study.

          -  Subject is unable to undergo MRI imaging because of having an artificial heart valve,
             metal plate, pin, or other metallic objects (including gun shots or shrapnel) in
             their body or is unable to complete all the five MRI scans required for this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Fox, MD, FAAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Layton</last_name>
      <phone>205-934-1885</phone>
      <email>blayton@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Khurram Bashir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janelle Butters, RN</last_name>
      <phone>916-734-6276</phone>
      <email>Janelle.butters@ucdmc.ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Randev Sandhu, CCRP</last_name>
      <email>rssandhu@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Agius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Canamar</last_name>
      <email>CCanamar@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jenny Bardens</last_name>
      <email>JBardens@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Callene Momtazee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Connelly</last_name>
      <phone>303-724-5128</phone>
      <email>kathryn.connelly@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>AJ Stein</last_name>
      <phone>303-724-6346</phone>
      <email>alexander.stein@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Augusto Miravalle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Rodriguez</last_name>
      <phone>305-243-8052</phone>
      <email>GRodriguez13@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Kottil Rammohan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kanoa Folami</last_name>
      <phone>404-778-3444</phone>
      <email>kfolami@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Neil Lava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pat Casey, MS</last_name>
      <phone>312-695-0774</phone>
      <email>Pcasey1@nmff.org</email>
    </contact>
    <contact_backup>
      <last_name>Linda Reisberg</last_name>
      <phone>312-695-0083</phone>
      <email>l-reisberg@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joy Derwenskus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Schmidt, LPN</last_name>
      <phone>913-588-3968</phone>
      <email>lschmidt@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Sharon Lynch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Cook, RN</last_name>
      <phone>617-525-6585</phone>
      <email>scook@partners.org</email>
    </contact>
    <investigator>
      <last_name>Christopher A Severson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Bozik</last_name>
      <email>abozik@partners.org</email>
    </contact>
    <investigator>
      <last_name>Eric Klawiter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St Louis</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mengesha Teshome</last_name>
      <email>teshomem@neuro.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Fox</last_name>
      <phone>314-362-2017</phone>
      <email>foxs@neuro.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Naismith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Patch, RN</last_name>
      <phone>718-920-6690</phone>
      <email>donna.patch@einstein.yu.edu</email>
    </contact>
    <investigator>
      <last_name>Corey McGraw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University at Buffalo, The State University of New York</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Patrick</last_name>
      <phone>716-859-7510</phone>
      <email>Kpatrick@buffalo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Zakalik</last_name>
      <email>kzakalik@buffalo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bianca Weinstock-Gutman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornell Medical College</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bill Nikolov</last_name>
      <phone>212-746-9882</phone>
      <email>Bln2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Jai Perumal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah E Gohs</last_name>
      <email>deg15@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Claire S Riley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Scheid</last_name>
      <phone>585-275-6673</phone>
      <email>Eileen_scheid@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Goodman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University at Stony Brook, The State University of New York</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Bower</last_name>
      <email>Traci.Bower@stoneybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia Coyle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University at Upstate, The State University of New York</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea McGlond</last_name>
      <phone>315-464-5302</phone>
      <email>mcglonda@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Burk Jubelt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati, Department of Neurology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Moeller</last_name>
      <email>moelleky@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Aram Zabeti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Mays</last_name>
      <phone>216-445-6339</phone>
      <email>maysj1@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Ontaneda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misty Cost</last_name>
      <email>misty.cost@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica DeJesus</last_name>
      <phone>614-366-3757</phone>
      <email>Jessica.DeJesus@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aaron Boster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Griffith</last_name>
      <phone>503-494-5759</phone>
      <email>griffide@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Vijayshree Yadav, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Oddis</last_name>
      <phone>412-692-4918</phone>
      <email>kmoddis@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Galen Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Scott, RN</last_name>
      <phone>615-322-4085</phone>
      <email>Jennifer.I.scott@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Harold Moses, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Hughes</last_name>
      <email>samuel.hughes@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Donna Graves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Floore, RN</last_name>
      <phone>801-585-5227</phone>
      <email>Tammy.floore@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sara Woltz</last_name>
      <email>sara.woltz@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dana DeWitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Charlottesville</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Keller, RN</last_name>
      <email>mfk8e@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Myla Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Wood</last_name>
      <email>Becky.Wood@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Beena Gangadharan</last_name>
      <email>benna.gangadharan@swedish.org</email>
    </contact_backup>
    <investigator>
      <last_name>Pavle Repovic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.neuronext.org</url>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>October 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ibudilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
